Clinical Trial Update: Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2 [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating chemotherapy plus monoclonal antibody therapy for HER2-positive breast cancer in women with Stage II/IIIA disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED